Abstracts tagged "Outcome measures"

Abstract Number: 1717 • ACR Convergence 2025
The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Mortality In Systemic Lupus Erythematosus (SLE) Patients: Data From The Almenara Lupus Cohort
Benny Rashuamán-Conche¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Anubhav Singh⁴, Cristina Reategui-Sokolova⁵, Claudia Elera-Fitzcarrald⁵, Samira Garcia-Hirsh⁶, Cesar Pastor-Asurza⁷, Zoila Rodriguez-Bellido⁸, Risto Perich-Campos⁹, Graciela Alarcón¹⁰ and Manuel Ugarte-Gil¹¹, ¹Hospital Guillermo Almenara Irigoyen, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Baptist hospital of southeast Texas, Beaumont, TX, ⁵Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁷Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁸Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁹Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ¹⁰The University of Alabama at Birmingham, Oakland, CA, ¹¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: Frailty has been shown to predict damage accrual in patients with SLE, including those from Latin America. However, the impact of frailty on mortality…
Abstract Number: 1430 • ACR Convergence 2025
Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis
Stylianos Georgiadis¹, Lykke Ørnbjerg¹, Brigitte Michelsen², Tore K. Kvien², Mehrdad Shoae Kazemi¹, Bente Glintborg¹, Anne Gitte Loft³, Rita Fonseca⁴, Helena Santos⁵, Andreas Reich⁶, Anne C. Regierer⁶, Jarno Rutanen⁷, Laura Kuusalo⁸, Gary Macfarlane⁹, Gareth T. Jones⁹, Adrian Ciurea¹⁰, Michael J. Nissen¹¹, Bjorn Gudbjornsson¹², Olafur Palsson¹³, Ziga Rotar¹⁴, Katja Perdan Pirkmajer¹⁵, Daniela Di Giuseppe¹⁶, Merete Hetland¹⁷ and Mikkel Ostergaard¹⁸, ¹Rigshospitalet, Glostrup, Denmark, ²Diakonhjemmet Hospital, Oslo, Norway, ³Aarhus University Hospital, Aarhus, Denmark, ⁴Unidade Local de Saúde de Entre Douro e Vouga, Santa Maria da Feira, Portugal, ⁵Instituto Português de Reumatologia, Lisbon, Portugal, ⁶German Rheumatology Research Center, Berlin, Germany, ⁷Tampere University Hospital, Tampere, Finland, ⁸Turku University Hospital, Turku, Finland, ⁹University of Aberdeen, Aberdeen, United Kingdom, ¹⁰University Hospital Zurich, Zurich, Switzerland, ¹¹Geneva University Hospital, Geneva, Switzerland, ¹²Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹³University of Iceland, Reykjavik, Iceland, ¹⁴University Medical Centre Ljubljana, Ziri, Slovenia, ¹⁵University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁶Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Stockholms Lan, Sweden, ¹⁷Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ¹⁸Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark
Background/Purpose: In patients with axial spondyloarthritis (axSpA), high disease activity is a key indication for biological disease-modifying antirheumatic drug (bDMARD) initiation. The Axial Spondyloarthritis Disease…
Abstract Number: 1126 • ACR Convergence 2025
Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
Coralie Tremblay¹, Nathalie Carrier², Hugues Allard-Chamard³, Javier Marrugo⁴, Sophie Roux⁴, Gilles Boire⁵ and Ariel Masetto⁴, ¹Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Saint-Augustin-de-Desmaures, QC, Canada, ²Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ³Université de Sherbrooke, Sherbrooke, Canada, ⁴Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Sherbrooke, Canada, ⁵Retired, Sherbrooke, QC, Canada
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common cause of arthropathy over the age of 60. It can also manifest as a chronic polyarticular…
Abstract Number: 0595 • ACR Convergence 2025
Sustained Remission In SLE Is Infrequent On Standard Of Care: A Decade Of Insights From The Asia Pacific Lupus Collaboration
Rangi Kandane-Rathnayake¹, Yi-Hsing Chen², Alberta Hoi³, Vera Golder⁴, Worawit Louthrenoo⁵, Jiacai Cho⁶, Aisha Lateef⁷, Laniyati Hamijoyo⁸, Shue Fen Luo⁹, Yeong-Jian Jan Wu¹⁰, Chiu Wai Shirley Chan¹¹, Leonid Zamora¹², Yasuhiro Katsumata¹³, Sargunan Sockalingam¹⁴, Zhanguo Li¹⁵, Haihong Yao¹⁵, BMDB Basnayake¹⁶, Yih Jia Poh¹⁷, Yanjie Hao¹⁸, Zhuoli Zhang¹⁹, Madelynn Chan²⁰, Jun Kikuchi²¹, Yuko Kaneko²², Tsutomu Takeuchi²³, Shereen Oon²⁴, Kristine Ng²⁵, Sang-Cheol Bae²⁶, Cherica Tee²⁷, Michael Tee²⁷, Nicola Tugnet²⁸, Sean O’Neill²⁹, Geraldine Hassett³⁰, Fiona Goldblatt³¹, Naoaki Ohkubo³², Yusuke Miyazaki³², Mark Sapsford³³, Yoshiya Tanaka³⁴, Sandra Navarra³⁵, Chak Sing Lau³⁶, Mandana Nikpour³⁷ and Eric Morand³⁸, ¹Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ²Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ³Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ⁴Monash University, Clayton, Australia, ⁵Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, Singapore, Singapore, ⁷Woodlands Health, Singapore, Singapore, ⁸Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, Badung, Indonesia, ⁹Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan, Taoyuan, Taiwan (Republic of China), ¹⁰Chang Gung Memorial Hospital, Chang Gung University, Taoyuan City, Taiwan (Republic of China), ¹¹Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ¹²University of Santo Tomas Hospital, Manila, Philippines, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴University of Malaya Medical Center, Kuala Lumpur, Malaysia, ¹⁵Peking University People's Hospital, Beijing, China (People's Republic), ¹⁶National Hospital Kandy, Kandy, Sri Lanka, ¹⁷Singapore General Hospital, Singapore, Singapore, ¹⁸St Vincent’s Hospital Melbourne, Fitzroy, Australia, ¹⁹Peking University First Hospital, Beijing, Beijing, China (People's Republic), ²⁰Tan Tock Seng Hospital, Singapore, Singapore, ²¹Keio University, Tokyo, Japan, ²²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²³Saitama Medical University and Keio University, Tokyo, Japan, ²⁴St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia, ²⁵Health New Zealand Waitemata, Te Whatu Ora, Auckland, New Zealand, ²⁶Hanyang University Medical Center, Seoul, South Korea, ²⁷University of the Philippines, Manila, Philippines, ²⁸Health New Zealand Auckland, Te Whatu Ora (Auckland District Health Board), Auckland, New Zealand, ²⁹The University of Sydney, Sydney, Australia, ³⁰Liverpool Hospital, NSW, Liverpool, Australia, ³¹Flinders Medical Centre, Bedford park, Australia, ³²University of Occupational and Environmental Health, Kitakyushu, Japan, ³³Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital),, Auckland, New Zealand, ³⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³⁵University of Santo Tomas, Manila, Philippines, ³⁶The University of Hong Kong, Hong Kong, Hong Kong, ³⁷University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia, ³⁸Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia
Background/Purpose: Treat-to-target (T2T) states in SLE, such as the Lupus Low Disease Activity State (LLDAS) and remission (REM) as defined by the Definitions of Remission…
Abstract Number: 0444 • ACR Convergence 2025
Low Disease Activity: Good Enough?
Emily Thoman¹, Sebastiano Porcu¹ and Martin Bergman², ¹Lankenau Medical Center, Wynnewood, PA, ²Drexel University College of Medicine, Philadelphia
Background/Purpose: Treat-to-target is the guiding principle and therapeutic strategy for rheumatoid arthritis (RA) treatment. Escalation of treatment is based on the regular assessment of disease…
Abstract Number: 0282 • ACR Convergence 2025
Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association with Patient-Reported Outcomes
Shiri Keret¹, Raisa Lomanto Silva², Irada Choudhuri³, Eugenia Gkiaouraki³, Tanya Chandra³, Nantakarn Pongtarakulpanit³, Shreya Sriram³, Niladri Bhowmick³, Vaidehi Kothari³, Kaushik Sreerama Reddy³, Eaman Alhassan⁴, Anushka Aggarwal⁵, Maha Almackenzie⁶, Siamak Moghadam-Kia⁴, Dana Ascherman⁷, Chester V. Oddis⁷ and Rohit Aggarwal⁸, ¹Bnai Zion Medical Center, Atlit, Israel, ²Massachusetts General Hospital, Boston, MA, ³University of Pittsburgh Medical Center, Pittsburgh, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Indraprastha Apollo Hospital, New Delhi, India, ⁶Medical Cities of the Ministry of the Interior, Riyadh, Saudi Arabia, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: The six myositis core set measures (CSMs) are widely utilized to assess disease activity in idiopathic inflammatory myopathies (IIM). However, their association with how…
Abstract Number: L10 • ACR Convergence 2024
Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study
John Tesser¹, Joshua June², Pendleton Wickersham³, Jane Box⁴, Guillermo Valenzuela⁵, Angela Crowley⁶, Nikila Kumar⁷, Norman Gaylis⁸, Gordan Lam⁹, David Ridley¹⁰, Gineth Paola Pinto-Patarroyo¹¹ and David Chernoff¹², ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Great Lakes Center of Rheumatology, Lansing, MI, ³Arthritis Associates PA, San Antonio, TX, ⁴DJL Clinical Research, PLLC, Charlotte, NC, ⁵Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, ⁶Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ⁷Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, ⁸Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁹Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹Annapolis Rheumatology, Fairfax, VA, ¹²SetPoint Medical, Sausalito, CA
Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
Abstract Number: 0155 • ACR Convergence 2024
Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients
Fizza Zulfiqar¹, Morgan Steele², Sharanya Shre Ezhilarasan Santhi³, Bryanna Singh², Jaisal Brar³, Sumit Raut³, Prami Nakarmi³, Samhitha Bitla Reddy³, Ojo Ayomide³, Bashar Roumia³, Fariha Tareen³, Nathan Crook³, Vanessa Drust³, Ahmed Fawzy Mohamed³, Asad Mohammad Jani³, Jennifer Orejuela³, Siena Captain³, Nikhil Vojalla³, Muhammad Bilal⁴, Rida Fatima⁴, Sanjana Kesireddy³, Paige Misner³, Rishab Prabhu³, Camelia Arsene³, Jawad Bilal⁵ and Jacky Duong³, ¹Trinity Health Oakland/Wayne State University, Pontiac, MI, ²Trinity Health Oakland, Pontiac, MI, ³Trinity Health Oakland, Pontiac, ⁴Bassett Medical Center, Cooperstown, NY, ⁵Southeast Tucson, Clinician Rheumatologist, Tuscon
Background/Purpose: COVID-19 has brought challenges for people with rheumatic diseases as well as those faced by the general population, such as increased risk of SARS-CoV-2…
Abstract Number: 0398 • ACR Convergence 2024
Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data
Mary Eckert¹, Eveline Wu², Melissa Oliver³, Joshua Scheck⁴, Sivia Lapidus⁵, Ummusen Kaya Akca⁶, Shima Yasin⁷, Aleksander Lenert⁸, Sara Stern⁹, Antonella insalaco¹⁰, Manuela Pardeo¹⁰, Gabriele Simonini¹¹, Edoardo Marrani¹², Xing Wang¹³, Bin Huang¹⁴, Leonard Kovalick¹⁵, Natalie Rosenwasser¹⁶, Erin Balay-Dustrude¹⁷, Gabriel Casselman¹⁶, Liau Adriel¹⁸, Ava Klein¹⁸, Yurong Shao⁴, Claire Yang⁴, Molly Briggs⁴, Emily Deng⁴, Iris Hamilton⁴, Ethan Mueller¹⁶, Elise Machrone⁴, Paige Trunnel⁴, Doaa Mosa¹⁹, Lori Tucker²⁰, Hermann Girschick²¹, Ronald Laxer²², Georgina Tiller²³, Jonathan Akikusa²⁴, Christian Hedrich²⁵, Karen Onel²⁶, Fatma Dedeoglu²⁷, Marinka Twilt²⁸, Seza Ozen²⁹, Polly Ferguson³⁰, Laura Schanberg³¹, Bryce Reeve³² and Yongdong (Dan) Zhao³³, ¹Seattle Children's, Mercer Island, WA, ²University of North Carolina School of Medicine, Chapel Hill, NC, ³Indiana University, Indianapolis, IN, ⁴Seattle Children's Hospital, Seattle, ⁵Hackensack University Medical Center, Montclair, NJ, ⁶Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ⁷University of Iowa Carver College of Medicine, Abu Dhabi, United Arab Emirates, ⁸University of Iowa, Iowa City, IA, ⁹University of Utah, Salt Lake City, UT, ¹⁰IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ¹¹Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, ¹²University of Florence, Firenze, Florence, Italy, ¹³Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, ¹⁴Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ¹⁵UNC Health Care, Durham, NC, ¹⁶Seattle Children's Hospital, Seattle, WA, ¹⁷University of Washington, Seattle, WA, ¹⁸Seattle Children’s Research Institute, University of Washington, Seattle, ¹⁹Mansoura University Hospital, Mansoura City, Egypt, ²⁰BC Children's Hospital, Vancouver, BC, Canada, ²¹Vivantes Clinic Friedrichshain, Wuerzburg, Germany, ²²SickKids, Toronto, ON, Canada, ²³University of British Columbia - Vancouver, Vancouver, BC, Canada, ²⁴Royal Children's Hospital, Parkville, Victoria, Australia, ²⁵University of Liverpool, Liverpool, United Kingdom, ²⁶HSS, New York, NY, ²⁷Boston Children's Hospital, Boston, MA, ²⁸Alberta Children's Hospital, Calgary, AB, Canada, ²⁹Department of Pediatrics, Hacettepe University, Ankara, Turkey, ³⁰University of Iowa Carver College of Medicine, Iowa City, IA, ³¹Duke University Medical Center, DURHAM, NC, ³²Duke University School of Medicine, Durham, ³³University of Washington, Redmond, WA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. It is critical to capture the child’s health-related quality of life impact using validated patient-reported…
Abstract Number: 0619 • ACR Convergence 2024
Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus
OKEOGHENE AKPOIGBE¹, BETTINA ESCOLANO², ENOCH J ABBEY² and Amanda Sammut³, ¹New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, ²New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, ³New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY
Background/Purpose: Systemic lupus erythematosus (SLE) complicated with hemophagocytic lymphohistiocystosis (HLH) can be life-threatening with mortality as high as 9.9%-10.5%. Estimates of the prevalence of HLH…
Abstract Number: 0739 • ACR Convergence 2024
One Year Outcomes in Those with Isolated PMR Recruited via a Fast Track PMR Clinic
Patricia Harkins¹, Sharon Cowley², Robert Harrington³, seoidin McKittrick⁴, David Kane⁵ and Richard Conway⁶, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³St. James's Hospital, Dublin, Dublin, Ireland, ⁴University of Limerick, Limerick, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: To date the longitudinal outcomes of those with isolated Polymyalgia Rheumatica (PMR) are poorly understood, owing largely to the fact that in the majority…
Abstract Number: 1051 • ACR Convergence 2024
Healthcare Costs and Resource Utilization Associated with Long-term Medium-to-high Dose Oral Corticosteroid Use in Patients with Dermatomyositis or Polymyositis
Daniel Labson¹, Qian Cai², Concetta Crivera³ and Federico Zazzetti⁴, ¹Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Raritan, NJ, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Titusville, NJ, ³Janssen Global Services, LLC, a Johnson & Johnson Company, Immunology Market Access, Horsham, PA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare autoimmune conditions primarily characterized by muscle weakness and inflammation. Real-world evidence on economic outcomes of patients with…
Abstract Number: 1428 • ACR Convergence 2024
A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren’s Disease Exploring the Novel Composite Endpoint Sjögren’s Tool for Assessing Response (STAR)
Wolfgang Hueber¹, Raphaele Seror², Raphael Porcher³, Gabriel Baron⁴, Linchen He⁵, Wen-Lin Luo⁵, Xavier Mariette⁶ and Peter Gergely¹, and the members of the NECESSITY IMI2 consortium, ¹Novartis Pharma, Basel, Switzerland, ²Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ³Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, ⁴Hôpitaux Universitaires Paris-Sud (AP-HP), Paris, Ile-de-France, France, ⁵Novartis Pharma, East Hanover, NJ, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Two randomized controlled phase 2 trials in patients with active Sjogren’s disease (SjD) were recently completed, the LOUiSSe trial assessing the Bruton Tyrosine kinase…
Abstract Number: 1617 • ACR Convergence 2024
Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission
Luigi Boiardi¹, Pierluigi Macchioni¹, Francesco Muratore², Chiara Marvisi¹, Caterina Ricordi¹, Annibale Versari¹, Giulia Besutti¹, Lucia Spaggiari¹, Stefania Croci¹ and Carlo Salvarani¹, ¹Azienda Sanitaria Locale, IRCSS, Reggio Emilia, Reggio Emilia, Italy, ²Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Aim of our study was to evaluate the persistence of imaging abnormalities in patients with Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA)…
Abstract Number: 2169 • ACR Convergence 2024
Different Trajectories of Patient Reported Outcomes in Patients with RA in a Stable Phase of Disease – an Observational Study
Paul Studenic¹, Nadine Schwab², Günther Zauner², Thi Lan Vi Tran³ and Helga Lechner-Radner⁴, ¹Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria, Vienna, Austria, ²dwh GmbH, simulation services, Vienna, Austria & Institute of Information Systems Engineering, TU Wien, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria
Background/Purpose: In patients with rheumatoid arthritis (RA), we often see a disconnect between patient and evaluator perceived disease activity. In this study we aim to…

« Previous Page
1
…
8
9
10
11
12
…
59
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].